It might be of comfort to the minister to know that, if she were minded to approve the continued prescribing of the drug, she would not be committing to a growing cost, as is likely in so many areas of cancer today, but one that will be, if not time limited, likely to reduce over time.A current problem is that if drug companies produce drugs that are design...